Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Accugenomics Inc. holds a patent portfolio in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This activity is situated within 1 distinct art unit. The concentration of filings in a single art unit suggests a focused approach to the company's current biotechnology developments. This focus can be used to build a specialized patent thicket within a specific technical domain.
The 1 distinct examiner assigned to the portfolio is ZEMAN, MARY K. As the busiest examiner, ZEMAN, MARY K is managing 1 busiest examiner pending office action. Because there is only 1 distinct examiner for the entire portfolio, current prosecution results depend on the review of this single individual. Practitioners can focus on the specific examination style of ZEMAN, MARY K, as there are no other examiners currently influencing the portfolio's direction. This centralized prosecution model minimizes the complexity of managing different examiner expectations within the Biotechnology & Pharmaceuticals area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZEMAN, MARY K | 1 | 58.9% | +34.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17374455 | ENDOGENOUS COMPLEXITY CALIBRATION LADDER TARGET | ZEMAN, MARY K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17374455 | ENDOGENOUS COMPLEXITY CALIBRATION LADDER TARGET | ZEMAN, MARY K | — |
| Art Unit | Apps |
|---|---|
| 1686 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17374455 | ENDOGENOUS COMPLEXITY CALIBRATION LADDER TARGET | ZEMAN, MARY K | 1686 | §101§102§103§112 | Non-Final OA | — | Pending | Jul 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAccugenomics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Mary K Zeman has the most, with 1 of Accugenomics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
